Stroke is the third most common cause of death and the leading cause of morbidity and long-term disability. The use of thrombolytic therapy such as that of tissue plasminogen activator MUST be administered within three hours of stroke onset to be effective in reversal/reduction of stroke injury. The objective of this project is to develop an individually addressable array of labeless affinity biosensors for the rapid detection of biochemical and neurochemical markers for stroke, facilitating the rapid diagnosis essential for introduction of thrombolytic therapy. Labeless affinity sensors integrated with sample manipulation on a disposable microsystem platform address the problem associated with rapid diagnosis of stroke by allowing cost-effective (typically 10 EURO), rapid (in minutes), specific (using novel monoclonal antibodies and aptamers) and sensitive (ng-pg/ml), detection of stroke markers for use at the point-of-care.
Funding SchemeCSC - Cost-sharing contracts
MK43 0AL Cranfield,bedford
3526 KL Utrecht
M1 7HS Manchester